Search results for "Neoplastic"

showing 10 items of 2901 documents

Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?

2015

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, i…

Maleendocrine system diseasesPrognosiSettore MED/06 - Oncologia MedicaMice NudeReviewDiseaseAdenocarcinomaMalignancymedicine.disease_causeMetastasisMicemicroRNABiomarkers TumorCarcinomamedicineAnimalsHumansmiRNAbiomarkers; miRNAs; pancreatic adenocarcinoma; prognosis; therapyAnimalbusiness.industryPancreatic NeoplasmbiomarkersMicroRNABiomarkerPrognosismedicine.diseasePhenotypedigestive system diseasesPancreatic NeoplasmsGene Expression Regulation NeoplasticMicroRNAsPhenotypeBiomarkers; miRNAs; Pancreatic adenocarcinoma; Prognosis; Therapy; Adenocarcinoma; Animals; Biomarkers Tumor; Carcinoma Pancreatic Ductal; Female; Gene Expression Regulation Neoplastic; Humans; Male; Mice; Mice Nude; MicroRNAs; Pancreatic Neoplasms; Phenotype; Prognosis; OncologyOncologymiRNAsImmunologyCancer researchAdenocarcinomaFemaleTherapybusinessCarcinogenesisPancreatic adenocarcinomaCarcinoma Pancreatic DuctalHuman
researchProduct

Correlation between EGFR Amplification and the Expression of MicroRNA-200c in Primary Glioblastoma Multiforme

2014

Extensive infiltration of the surrounding healthy brain tissue is a critical feature in glioblastoma. Several miRNAs have been related to gliomagenesis, some of them related with the EGFR pathway. We have evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns, studied by fluorescence in situ hybridization in tissue microarrays, of 30 cases of primary glioblastoma multiforme, whose clinicopathological and immunohistochemical features have also been analyzed. MicroRNA-200c showed a very significant difference between tumors having or not EGFR amplification. This microRNA plays an important role in epithelial-mesenchymal transition, but its impl…

Malelcsh:MedicineGene expressionGene duplicationMedicine and Health Scienceslcsh:ScienceNeurological TumorsIn Situ Hybridization FluorescenceMultidisciplinaryTissue microarraymedicine.diagnostic_testBrain NeoplasmsCancer Risk FactorsGliomaMiddle AgedCadherinsErbB ReceptorsGene Expression Regulation NeoplasticNeurologyOncologyImmunohistochemistryFemaleDNA microarrayResearch ArticleSignal TransductionEpithelial-Mesenchymal TransitionGenetic Causes of CancerBiologyYoung AdultmicroRNAmedicineGeneticsCancer GeneticsHumansEpithelial–mesenchymal transitionAgedHomeodomain Proteinslcsh:RGene AmplificationBiology and Life SciencesCancers and NeoplasmsZinc Finger E-box-Binding Homeobox 1Molecular biologySurvival AnalysisMicroRNAsTissue Array AnalysisGenetics of DiseaseCancer researchlcsh:QGlioblastomaGlioblastoma MultiformeFluorescence in situ hybridizationTranscription FactorsPLoS ONE
researchProduct

Synergistic effect of peplomycin in combination with bleomycin on L5178y mouse lymphoma cells in vivo.

1984

Studying the treatment of NMRI mice with ip injections of bleomycin (BLM) for 5 days we found an approximate LD50 of 35 mg/kg; the toxicity of peplomycin (PEP) was slightly higher (LD50: approximately 25 mg/kg). The effect of the two drugs on growth of L5178y mouse lymphoma cells in NMRI mice was examined. BLM alone caused at a concentration of 2.5 mg/kg an almost complete inhibition of tumor cell growth; the same effect was determined with 1 mg PEP/kg. At these concentrations the drugs caused an increase of the survival time of 110% (BLM) or 104% (PEP). Given in combination, one-sixth of the optimal doses yielded an 100% increase of the median survival time. These results indicate a signif…

Malemedicine.drug_classCell SurvivalAntibioticsPharmacologyBiologyBleomycinchemistry.chemical_compoundBleomycinMicePeplomycinIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsLeukemia L5178PharmacologyLeukemia Experimentalurogenital systemCell growthMouse LymphomaBiological activityDrug SynergismchemistryToxicityImmunologyPeplomycinThe Journal of antibiotics
researchProduct

Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment acco…

1984

The thrombocyte count, the factor XIII (F XIII) activity, the concentration of fibrinogen (F I), prothrombin (F II), fibronectin (CIG), albumin and the proteinase inhibitors antithrombin III (AT III), alpha 2-macroglobulin (A2M), alpha 1-antitrypsin (A1A) and Cl-esterase inactivator (Cl-INA) were determined in ten children with acute lymphoblastic leukaemia (ALL). Changes due to the disease and to therapy were observed. Before the start of treatment the patients had thrombocytopenia secondary to the disease, and the proteinase inhibitors--especially Cl-INA and A1A--were raised. During the induction phase the thrombocyte count rose but there was also a marked increase in the concentration of…

Malemedicine.medical_specialtyAdolescentAntithrombin IIIAlpha (ethology)Complement C1 Inactivator ProteinsFibrinogenMaintenance therapyInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtease Inhibitorsalpha-MacroglobulinsChildGenetics (clinical)Factor XIIIbusiness.industryAntithrombinAlbuminFibrinogenGeneral MedicineFactor XIIIMolecular medicineBlood Coagulation FactorsFibronectinsLeukemia LymphoidEndocrinologyCoagulationChild Preschoolalpha 1-AntitrypsinImmunologyMolecular MedicineFemaleProthrombinbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Nephroblastoma: does the decrease in tumor volume under preoperative chemotherapy predict the lymph nodes status at surgery?

2011

Background Partial nephrectomy (NSS) for unilateral nephroblastoma may be beneficial, although in case of regional lymph node (LN) involvement, radiotherapy counteracts the functional benefit of NSS. The aim is to verify whether decrease of tumor volume under preoperative chemotherapy implies clearance of regional LN. Procedure SIOP 9301 (1993–2001) collected 1,450 localized nephroblastoma patients of whom 1,360 (93%) had sufficiently available data and were retrospectively reviewed. Results Histologic subtypes were classically distributed. Patients were divided in those with tumor positive LN (76, 5.5%) and those with tumor negative LN (1,284, 94.5%) at surgery. In the LN(+) group, the tum…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntineoplastic AgentsWilms TumorInterquartile rangemedicineHumansChildLymph nodeNeoadjuvant therapyNeoplasm StagingRetrospective StudiesChemotherapybusiness.industryInfantWilms' tumorHematologymedicine.diseaseKidney NeoplasmsNeoadjuvant TherapyNephrectomySurgeryRadiation therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantChild PreschoolLymphatic MetastasisPediatrics Perinatology and Child HealthFemaleLymphbusinessPediatric Blood & Cancer
researchProduct

A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children

2012

Given that the rationale for empirical antifungal therapy in neutropenic children is limited and based on adult patient data, we performed a prospective, randomized, controlled trial that evaluated 110 neutropenic children with persistent fever. Those at high risk for invasive fungal infections (IFI) received caspofungin (Arm C) or liposomal amphotericinB (Arm B); those with a lower risk were randomized to receive Arm B, C, or no antifungal treatment (Arm A). Complete response to empirical antifungal therapy was achieved in 90/104 patients (86·5%): 48/56 at high risk (85·7%) [88·0% in Arm B; 83·9% in Arm C (P = 0·72)], and 42/48 at low risk (87·5%) [87·5% in control Arm A, 80·0% Arm B, 94·1…

Malemedicine.medical_specialtyAntifungal AgentsNeutropeniaAntineoplastic AgentsOpportunistic InfectionsLower riskFever of Unknown Originlaw.inventionEchinocandinsLipopeptideschemistry.chemical_compoundRandomized controlled trialCaspofunginlawAmphotericin BInternal medicinemedicineHumansProspective StudiesChildProspective cohort studyempirical antifungal therapy children cancerbusiness.industryPatient SelectionInfantCancerHematologyLength of Staymedicine.diseaseConfidence intervalSurgeryHospitalizationTreatment OutcomeMycoseschemistryChild PreschoolFemaleCaspofunginbusinessEmpiric therapyFebrile neutropeniaBritish Journal of Haematology
researchProduct

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with…

2002

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens. Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, g…

Malemedicine.medical_specialtyAntimetabolites AntineoplasticPalliative careTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSalvage therapyAntineoplastic AgentsIrinotecanGastroenterologyFolinic acidInternal medicineMucositisMedicineHumansNeoplasm MetastasisInfusions IntravenousAgedRetrospective StudiesSalvage TherapyChemotherapybusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicOxaliplatinSurgeryIrinotecanOxaliplatinFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells

2006

Two isoforms of cyclooxygenase (COX) are known, and to date most studies have implicated COX-2 in the development and progression of various human cancers. Increasing evidence suggests that COX-1 may also play a similar role. Indeed, we have recently observed that the dual COX-1/COX-2 inhibitor indomethacin induces apoptosis in human hepatocellular carcinoma (HCC) cell lines more effectively than the selective COX-2 inhibitors, possibly implicating COX-1 in HCC. In this study we investigated the expression of COX-1 in non-tumor and malignant human liver tissues, as well as the effects of the highly selective COX-1 inhibitor SC-560 on cell growth and apoptosis in human HCC cell lines. Expres…

Malemedicine.medical_specialtyCarcinoma HepatocellularCellApoptosisBiologyGene Expression Regulation EnzymologicCell Line TumorInternal medicineSurvivinGeneticsmedicineHumansCyclooxygenase InhibitorCyclooxygenase InhibitorsRNA MessengerAgedCell ProliferationOncogeneCell growthApoptosiGeneral MedicineMiddle AgedCell cycleImmunohistochemistryXIAPGene Expression Regulation NeoplasticEndocrinologymedicine.anatomical_structureCyclooxygenase 2ApoptosisCell culturePyrazoleCyclooxygenase 1Cancer researchPyrazolesFemaleHumanInternational Journal of Molecular Medicine
researchProduct

Chemoembolization for primary liver cancer

2002

Abstract Aims: For most patients with primary liver cancer surgical treatment is not feasible and prognosis without treatment is poor. We aimed to assess the morbidity and efficacy of transarterial chemoembolization (TACE) with lipiodol and mitomycin C in these patients in a prospective case-control study. Methods: From August 1996 to May 2000 22 patients with non-resectable hepatocellular carcinoma were treated with TACE. In case of radiological or tumour-marker response, treatment was repeated after 4–6 weeks, up to seven times per patient. Results: Morbidity was 23% and usually minor, no patient died within 30 days of treatment. A decrease in size of the reference tumour or constant tumo…

Malemedicine.medical_specialtyCarcinoma HepatocellularMitomycinmedicine.medical_treatmentGastroenterologyInternal medicinemedicineHumansProspective StudiesEmbolizationChemoembolization TherapeuticSurvival rateAgedAged 80 and overChemotherapyAntibiotics Antineoplasticbusiness.industryLiver NeoplasmsMitomycin CIodized OilGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateOncologyCase-Control StudiesRadiological weaponHepatocellular carcinomaLipiodolFemaleSurgeryalpha-FetoproteinsComplicationbusinessmedicine.drugEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Midterm follow-up after DC-BEAD™-TACE of Hepatocellular Carcinoma (HCC)

2012

Abstract Aim To determine local response, its predictors and survival and complication rates after DC-Bead™-TACE in patients with hepatocellular carcinoma (HCC). Materials and methods DC-Beads™ are non-resorbable, polyvinyl-alcoholic hydrophilic microspheres. They release high amounts of chemotherapeutics directly into the tumour. Delivery is sustained over time, tumour feeders are embolised. We used beads from 100–300 to 500–700 μm loaded with Doxorubicin (max. 150 mg/4 ml). Fifty patients (mean age: 68.5 ± 8.8 years) with HCC were analysed. DC-Bead™-TACE was performed once or repeated in two-month intervals. Imaging scans (CT or MRI) were done one-month following each procedure. To evalua…

Malemedicine.medical_specialtyCarcinoma HepatocellularPleural effusionAntineoplastic AgentsComorbidityGastroenterologyRisk FactorsGermanyInternal medicinePrevalencemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingChemoembolization TherapeuticSurvival rateSurvival analysisAgedUltrasonographybusiness.industryLiver NeoplasmsGeneral Medicinemedicine.diseaseSurvival AnalysisSurgerySurvival RateTreatment OutcomeDoxorubicinDelayed-Action PreparationsHepatocellular carcinomaFemaleLiver functionbusinessProgressive diseaseFollow-Up StudiesLiver abscessEuropean Journal of Radiology
researchProduct